Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02392429 · ClinicalTrials.gov registry record · Phase 2

FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia

A Phase 2 study of Acute Myeloid Leukemia, sponsored by National Cancer Institute (NCI).

Active
Registry status
Phase 2
Development phase
87
Enrollment target
11
Study locations

NCT02392429 is a Phase 2 study of Acute Myeloid Leukemia that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 87 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (25% lower). The trial reports 11 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02392429, a Phase 2 study of Acute Myeloid Leukemia, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
87 participants
Enrollment target
11
Study locations

Study Summary

This phase II trial studies fluorothymidine F 18 (FLT) positron emission tomography (PET)/computed tomography (CT) in measuring response in patients with previously untreated acute myeloid leukemia. FLT is a radioactive substance that may "light up" where cancer is in the body. FLT is injected into the blood and builds up in cells that are dividing, including cancer cells. Diagnostic procedures, such as PET/CT, may help measure a patient's response to earlier treatment.

Conditions Studied

Acute Myeloid Leukemia

Interventions

  • PROCEDURE Biospecimen Collection
  • PROCEDURE Bone Marrow Aspiration
  • PROCEDURE Bone Marrow Biopsy
  • PROCEDURE Computed Tomography
  • DRUG Chemotherapy

Study Locations (11)

Pennsylvania

  • University of Pennsylvania/Abramson Cancer Center - Philadelphia
  • Fox Chase Cancer Center - Philadelphia

Minnesota

  • Mayo Clinic in Rochester - Rochester

Missouri

  • Washington University School of Medicine - St Louis

New York

  • Mount Sinai Hospital - New York

North Carolina

  • UNC Lineberger Comprehensive Cancer Center - Chapel Hill

Oklahoma

  • University of Oklahoma Health Sciences Center - Oklahoma City

Tennessee

  • Vanderbilt University/Ingram Cancer Center - Nashville

Texas

  • UT Southwestern/Simmons Cancer Center-Dallas - Dallas

Trial Details

FieldValue
Enrollment Target 87 participants
Start Date 2016-04-20
Est. Completion 2027-02-13
Phase Phase 2

Sponsor

National Cancer Institute (NCI)

3,257 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02392429

The ClinicalTrials.gov registry entry for NCT02392429 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (25% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT02392429 reports 11 study locations spanning 10 distinct geographic areas - top geographies include Pennsylvania, Minnesota, Missouri.

Frequently Asked Questions

What is clinical trial NCT02392429 about?

NCT02392429 is a clinical study titled "FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia". This phase II trial studies fluorothymidine F 18 (FLT) positron emission tomography (PET)/computed tomography (CT) in measuring response in patients with previously untreated acute myeloid leukemia. FLT is a radioactive substance that may "light up" where cancer is in the body. FLT is injected into ...

What is the current status of trial NCT02392429?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2016-04-20. Estimated completion is 2027-02-13.

What conditions does trial NCT02392429 study?

This clinical trial studies the following conditions: Acute Myeloid Leukemia.

What interventions are being tested in trial NCT02392429?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Bone Marrow Aspiration (PROCEDURE), Bone Marrow Biopsy (PROCEDURE), Computed Tomography (PROCEDURE), Chemotherapy (DRUG).

Who is sponsoring clinical trial NCT02392429?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02392429 being conducted?

This trial has 11 study locations across Minnesota, Missouri, New York, North Carolina, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Myeloid Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acute Myeloid Leukemia

All registered trials for this condition

Minnesota

All trials with a study site in Minnesota

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.